化疗是非小细胞肺癌治疗的主要手段之一，而耐药是影响化疗疗效的重要因素。切除修复交叉互补基因1是核苷酸切除修复的关键基因，其基因表达及基因多态性与铂类耐药存在相关性，从而影响非小细胞肺癌对化疗敏感性及疗效。

Chemotherapy is one of the principal means of combined therapy in non-small cell lung cancer, but drug resistance is the major factor that impairs the therapeutic effect. Excision repair cross-complementation group 1 (ERCC1) is the key gene for nucleotide excision repair. Its expression and polymorphisms are related to platinum resistance, which may affect the chemotherapy sensititivity and efficacy for non-small cell lung cancer.

［1］Van Duin M, De Wit J,Odijk H,et al. Molecular characterir  zation of  the  human excision repair gene ERCC-1:cDNA cloning and amino acid  homology with the yeast DNA repair gene RAD10［J］. Cell,1986,44(6):913-923.
［2］Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predict or of survival in resected patients with non-small cell lung cancer［J］. Chest, 2005, 127(3):978-983.
［3］Olaussen K, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy［J］. N Engl J Med，2006，355(10):983-991.
［4］Fujii T, Toyooka S, Ichimura K, et al. ERCC1 predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer［J］. Lung Cancer, 2008,59(3):377-384.
［5］Kondo K, Fujino H, Takizawa H, et al. ERCC1 expression is one of prognostic factors in completely resected non-small cell lungcancer patients with an adjuvant-platinum based chemotherapy［J］. Thorac Oncol，2007,2(8):S646.
［6］Holm B, Mellemgaard A, Skov T, et al. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine［J］.J Clin Oncol,2009,27(26):4254-4259.
［7］Cepeda V, Fuertes MA, Castilla J, et al. Biochemical mechanisms of cisplatin cytotoxicity［J］. Anticancer Agents Med Chem, 2007, 7(1):3-18.
［8］Zienolddiny  S,  Campa  D,  Lind  H,  et  al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer［J］. Carcinogenesis， 2006,27(3):560-567.
［9］Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer［J］. Cancer Epidemiol Biomarkers Prev，2005,14(2):491-496.
［10］Yuan P, Miao XP, Zhang XM,et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy［J］. Ai Zheng, 2005, 24(12):1510-1513.
［11］Viguier J, Boige V, Miquel C,et al.ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer［J］. Clin Cancer  Res, 2005, 11(17):6212-6217.
［12］Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer［J］. Lung Cancer，2007, 56(2):281-288.
［13］Kang S, Ju W, Kim  JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer［J］. Exp Mol Med, 2006,38(3):320-324.
［14］Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer［J］. Clin Lung Cancer, 2009, 10(2):118-123.
［15］Reed E. ERCC1 measurements in clinical oncology［J］. N Engl J Med, 2006, 355(10):1054-1055.
［16］Smith S, Su D, Rigault de la Longrais IA, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benet from paclitaxel treatment in addition to platinum- based therapy［J］. J Clin Oncol，2007,25(33):5172-5179.
［17］Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small cell lung cancer［J］. Ann Oncol，2004,15(8):1194-1203.
［18］ Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross -complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy［J］. Clin Cancer Res，2004,10(15):4939-4943.
［19］Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients［J］. Clin Cancer Res, 2005,11(4):1534-1538.